Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Fresenius Kabi surrenders AU adalimumab patent the subject of Court challenge by Samsung Bioepis

Jul 11, 2019

We previously reported that Samsung Bioepis commenced proceedings in July 2019 in the AU Federal Court seeking to revoke an adalimumab formulation and use patent owned by Fresenius Kabi.  In an interesting development, Fresenius Kabi surrendered the patent in the patent office on 12 November 2019.